# Question 39

**Type:** Mutation Subtype Analysis

**Question:** "What are the survival differences between EGFR-mutated, EGFR-amplified, and EGFR wild-type lung adenocarcinoma patients?"

**Answer:**

**URL**: https://www.cbioportal.org/results/comparison?Action=Submit&RPPA_SCORE_THRESHOLD=2.0&Z_SCORE_THRESHOLD=2.0&cancer_study_list=luad_tcga_pan_can_atlas_2018&case_set_id=luad_tcga_pan_can_atlas_2018_cnaseq&data_priority=0&gene_list=EGFR&geneset_list=%20&genetic_profile_ids_PROFILE_COPY_NUMBER_ALTERATION=luad_tcga_pan_can_atlas_2018_gistic&genetic_profile_ids_PROFILE_MUTATION_EXTENDED=luad_tcga_pan_can_atlas_2018_mutations&profileFilter=0&tab_index=tab_visualize

This URL takes you to the **Comparison/Survival** page in cBioPortal for the TCGA PanCancer Atlas Lung Adenocarcinoma study, with EGFR queried for both mutations and copy number alterations.

**What you'll see:**
- The page automatically groups samples into: EGFR altered (mutations and/or amplifications) vs. unaltered (wild-type)
- Navigate to the **Survival** tab to view Kaplan-Meier curves comparing overall survival between these groups
- You can further refine groups using the **Group Comparison** features to separate EGFR-mutated from EGFR-amplified cases for more granular survival analysis

This will allow you to explore the survival differences between these EGFR alteration subtypes in lung adenocarcinoma patients.

---

## Model Information
- **model**: us.anthropic.claude-sonnet-4-5-20250929-v1:0
- **temperature**: 0.0
- **max_output_tokens**: 1024
- **thinking_enabled**: False
- **thinking_budget_tokens**: 1024
- **response_time_seconds**: 7.955234905937687
- **agent_type**: cbio-nav-null

### Usage
- **input_tokens**: 566
- **output_tokens**: 391
- **total_tokens**: 957
- **cache_creation_input_tokens**: 0
- **cache_read_input_tokens**: 0

---

*Generated on 2026-02-05 01:38:50*